Fig. 6.

A low dose of clenbuterol reduces hepatic steatosis and hepatic glycogen. (a–e) DIO mice were treated with clenbuterol for 32 days; n = 9–10, both males and females were used. Diet-induced obesity was developed in C57Bl/6N mice maintained at 30°C and on HFD for 7 months; 3 mg/l clenbuterol was administered in drinking water; mean actual dose of clenbuterol calculated based on water intake was 0.16 mg kg⁻¹ day⁻¹; mice were fasted for 5 h in the morning before dissections. (a) Representative fluorescent images of liver lipid droplets stained with BODIPY (green, lipid); scale bars, 50 μm. Quantification of images in (a) using ImageJ, in terms of total area of lipid droplets (b), size (c) and number of lipid droplets (d). (e) Liver glycogen. (f) Pyruvate tolerance test was performed after 9 days of treatment during the same experiment as in Figs 4, 5 and ESM Fig. 2. The data were analysed with unpaired two-tailed Student’s t test in (b–e) and AUC in (f). In all graphs: *p < 0.05, **p < 0.01 vs vehicle